More stories

Revive Therapeutics Ltd. Announces Offering of Up to $5 Million

TORONTO, Nov. 30, 2022 (GLOBE NEWSWIRE) — REVIVE THERAPEUTICS LTD. (CSE: RVV; OTCQB: RVVTF) (“ Revive” or the “Company”) is pleased to announce that...

Clearmind Announces Initiation of CMND-100 Manufacturing Program to Address its Upcoming Clinical Trial

VANCOUVER, Nov. 23, 2022 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (Nasdaq: CMND), (CSE: CMND), (FSE: CWY) (“ Clearmind” or the “Company“), a biotech company...

Many Trips, Diminishing Returns: Cross-Tolerance Between LSD and DOI

Clinical interest in the use of psychedelic drugs for the treatment of psychiatric disorders has recently exploded, with researchers testing the effects of compounds...

PT375 – Microdosing & Citizen Science: Introducing the World’s First Take-Home EEG Microdosing Study

In this episode, Victoria hosts a bit of a microdosing roundtable, speaking with three champions of microdosing: “The Father of modern microdosing,” James Fadiman,...

Small Pharma to Participate in November Investor and Healthcare Conferences

LONDON, Nov. 11, 2022 (GLOBE NEWSWIRE) — Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “ Company” or “Small Pharma”), a biotechnology company focused...

Silo Pharma Initiates Study of Novel Joint Homing Peptide in Human Tissue

Initial data from study expected in first quarter 2023 ENGLEWOOD CLIFFS, NJ, Nov. 21, 2022 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (Nasdaq: SILO) (“the...

Tryp Therapeutics Announces Poster Presentations on the Reduction of Chronic Pain in a Rodent...

KELOWNA, British Columbia, Nov. 10, 2022 (GLOBE NEWSWIRE) — Tryp Therapeutics, Inc. (CSE: TRYP) (OTCQB: TRYPF) (“Tryp” or the “Company“), a clinical-stage biotechnology company...

Psychedelics Weekly – Bipartisan Political Movement & Psychedelics and Pain

This week features David Drapkin, Joe Moore (for the first part), and introduces Alexa Jesse, who you’ve probably heard in ads, but who makes...

How To Stop A Psychedelic Trip: The Promise of Ketanserin

A trip, as a direct cause of ingesting psychedelics, can be both healing and exhilarating. Giddy feelings, melting walls, and merging of yourself with...

Numinus to Participate in a Water Tower Research Fireside Chat on Thursday, December 8,...

VANCOUVER, BC, Nov. 22, 2022 /PRNewswire/ – Numinus Wellness Inc. (“Numinus” or the “Company”) (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing...

atai Life Sciences and Massachusetts General Hospital Announce Initiation of Clinical Study Investigating Neuroplasticity...

NEW YORK and BERLIN, Nov. 17, 2022 (GLOBE NEWSWIRE) — atai Life Sciences N.V. (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform...

FILAMENT HEALTH ANNOUNCES PSILOCYBIN SUPPLY AGREEMENT WITH THE CENTRE FOR ADDICTION AND MENTAL HEALTH

CAMH to use Filament’s natural psilocybin drug candidate for a clinical trial studying treatment-resistant depression VANCOUVER, BC, Nov. 17, 2022 /CNW/ – Filament Health...

Most popular